The Feasibility and Applicability of Stem Cell Therapy for the Cure of Type 1 Diabetes

Ryota Inoue; Kuniyuki Nishiyama; Jinghe Li; Daisuke Miyashita; Masato Ono; Yasuo Terauchi; Jun Shirakawa

doi:10.3390/cells10071589

Cells (Jun 2021)

The Feasibility and Applicability of Stem Cell Therapy for the Cure of Type 1 Diabetes

Ryota Inoue,
Kuniyuki Nishiyama,
Jinghe Li,
Daisuke Miyashita,
Masato Ono,
Yasuo Terauchi,
Jun Shirakawa

Affiliations

Ryota Inoue: Laboratory of Diabetes and Metabolic Disorders, Institute for Molecular and Cellular Regulation (IMCR), Gunma University, Maebashi 371-8512, Japan
Kuniyuki Nishiyama: Laboratory of Diabetes and Metabolic Disorders, Institute for Molecular and Cellular Regulation (IMCR), Gunma University, Maebashi 371-8512, Japan
Jinghe Li: Laboratory of Diabetes and Metabolic Disorders, Institute for Molecular and Cellular Regulation (IMCR), Gunma University, Maebashi 371-8512, Japan
Daisuke Miyashita: Department of Endocrinology and Metabolism, Graduate School of Medicine, Yokohama City University, Yokohama 236-0004, Japan
Masato Ono: Department of Endocrinology and Metabolism, Graduate School of Medicine, Yokohama City University, Yokohama 236-0004, Japan
Yasuo Terauchi: Department of Endocrinology and Metabolism, Graduate School of Medicine, Yokohama City University, Yokohama 236-0004, Japan
Jun Shirakawa: Laboratory of Diabetes and Metabolic Disorders, Institute for Molecular and Cellular Regulation (IMCR), Gunma University, Maebashi 371-8512, Japan

DOI: https://doi.org/10.3390/cells10071589
Journal volume & issue: Vol. 10, no. 7
p. 1589

Abstract

Read online

Stem cell therapy using islet-like insulin-producing cells derived from human pluripotent stem cells has the potential to allow patients with type 1 diabetes to withdraw from insulin therapy. However, several issues exist regarding the use of stem cell therapy to treat type 1 diabetes. In this review, we will focus on the following topics: (1) autoimmune responses during the autologous transplantation of stem cell-derived islet cells, (2) a comparison of stem cell therapy with insulin injection therapy, (3) the impact of the islet microenvironment on stem cell-derived islet cells, and (4) the cost-effectiveness of stem cell-derived islet cell transplantation. Based on these various viewpoints, we will discuss what is required to perform stem cell therapy for patients with type 1 diabetes.

Published in Cells

ISSN: 2073-4409 (Online)
Publisher: MDPI AG
Country of publisher: Switzerland
LCC subjects: Science: Biology (General): Cytology
Website: https://www.mdpi.com/journal/cells

About the journal

Abstract

Keywords